✦ LIBER ✦

Pemetrexed improves survival in pancreatic cancer

✍ Scribed by Li Wan

Book ID: 117784255
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 47 KB
Volume: 8
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(07)70066-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pemetrexed improves survival in mesothel

Pemetrexed improves survival in mesothelioma

✍ Susan Mayor 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 173 KB

Pemetrexed in pancreatic cancer

✍ Hedy Lee Kindler 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Pemetrexed combination improves mesothel

Pemetrexed combination improves mesothelioma survival

✍ Cathel Kerr 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 56 KB

Endosonographic Evaluation Improves Surv

Endosonographic Evaluation Improves Survival in Patients with Pancreatic Cancer

✍ Feng Li; Ying Zhou; Amitabh Chak; Gregory S. Cooper; Ananya Das 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

The pemetrexed/gemcitabine combination i

The pemetrexed/gemcitabine combination in pancreatic cancer

✍ Hedy Lee Kindler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Gemcitabine has modest antitumor activity in advanced pancreatic cancer. New agents are clearly needed. Pemetrexed (ALIMTA) is a novel antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has shown in vitro activity agai

VEGF antisense therapy inhibits tumor gr

VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer

✍ Hubert G. Hotz; O. Joe Hines; Rizwan Masood; Birgit Hotz; Thomas Foitzik; Heinz 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 329 KB